 | | Vol. 6.05 – 22 February, 2021 |
| |
|
|
| Researchers employed RNA sequencing to characterize transcriptional alterations of endothelial cells isolated from primary and secondary human brain tumors.
[Neuro-Oncology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To better understand the roles of intratumoral Tregs, the authors selectively depleted tumor-infiltrating T regulatory cells using anti-CD25-F(ab′)2 near-infrared photoimmunotherapy.
[Cancer Research] |
|
|
|
| Researchers showed that mutations in epidermal growth factor receptor (EGFR) stimulate the capacity of glioma cells to function as pericytes in a bone marrow and X-linked and SOX9-dependent manner.
[Cancer Research] |
|
|
|
| The authors investigated the glioblastoma microenvironment with transgenic lineage-tracing models, intravital imaging, single-cell transcriptomics, immunofluorescence analysis as well as histopathology and characterized a previously unacknowledged population of tumor-associated cells with a myeloid-like expression profile that transiently appeared during glioblastoma growth.
[Cell Systems] |
|
|
|
| Using SOX17-knockout and SOX17-inducible human pluripotent stem cells (hPSCs), paired with molecular profiling studies, researchers revealed that SOX17 was a master regulator of HOXA and arterial programs in hemogenic endothelium (HE) and was required for the specification of HE with robust lympho-myeloid potential and DLL4+CXCR4+ phenotype resembling arterial HE at the sites of HSC emergence.
[Cell Reports] |
|
|
|
| The authors investigated the regulation of specific long non-coding RNAs on the progression of ischemia/reperfusion injury. They identified and characterized the exosomes derived from mouse primary aortic endothelial cells.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Short and long-term engraftment were comparable for an engineered endothelial cell line (E-HUVEC) expanded and the non-expanded hematopoietic stem and progenitor cell (HSPCs) in both animals, despite extensive proliferation of CD34+ cells during eight days of ex vivo culture for the E-HUVEC HSPCs, and optimization of harvesting and infusion of HSPCs co-cultured on E-HUVEC in the second animal.
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
| Investigators evaluated tissue-based angiogenesis markers for potential predictive value regarding response to neoadjuvant bevacizumab treatment in breast cancer.
[Scientific Reports] |
|
|
|
| Researchers determined the effect of different types of nanoparticles on human endothelial cells and examined the types of toxicity responses they could induce.
[Scientific Reports] |
|
|
|
| Investigators hypothesized that VEGF-induced vascular leak acutely slowed action potential propagation in the atria and increased arrhythmia risk by disrupting intercalated disk nanodomains, and protection of the vascular barrier could prevent vascular leak-induced atrial arrhythmias.
[Biophysical Journal] |
|  |
|
|
|
| Investigators examined the recent investigations of hemato-endothelial ontogeny and recently reported progress for the conversion of pluripotent stem cells (PSC) and other promising somatic cell types towards HSCs with the focus on the crucial and inevitable role of the hemogenic endothelium to achieve the long-standing goal—to generate therapeutically applicable PSC-derived HSCs in vitro.
[Cellular and Molecular Life Sciences] |
|
|
|
| Critical features, known as the hallmarks of metastasis, include motility and invasion, modulation of the microenvironment, cell plasticity and colonization. They are hierarchically regulated at different levels by several factors, including galectins, a highly conserved family of β-galactoside-binding proteins abundantly expressed in tumor microenvironments and sites of metastasis.
[Biochemical Journal] |
|
|
|
| The authors highlight how knowledge of vascular endothelial cell (EC) development in vivo is used to differentiate induced pluripotent stem cells into ECs.
[Frontiers in Cardiovascular Medicine] |
|
|
|
|
| Trefoil Therapeutics announced it has begun a Phase II clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a regenerative treatment for patients with Fuchs Endothelial Corneal Dystrophy
[Trefoil Therapeutics] |
|
|
|
| In November 2020, the FDA granted Regenerative Medicine Advanced Therapy designation for a cellular therapy called AB-205. AB-205 acts promptly to repair injured vascular niches of organs to prevent or reduce severe toxicities in patients who have Hodgkin lymphoma or non-Hodgkin lymphoma undergoing high dose chemotherapy and autologous stem cell transplantation.
[Hackensack University Medical Center (Newswise, Inc.)] |
|
|
|
|
|
|
|
| | Imperial College London – London, England, United States |
|
|
|
| | University of California, San Diego – La Jolla, California, United States |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | F. Hoffmann-La Roche AG – Basel, Switzerland |
|
|
|
| | University of California San Francisco – San Francisco, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
